LG Chem's AVEO Oncology Presents RCC Drug Clinical Trial Results at 2024 ESMO

MT Newswires Live09-18

LG Chem's (KRX:051910) AVEO Oncology presented the Phase 3 clinical trial results of TiNivo-2 in patients with advanced metastatic renal cell carcinoma (RCC) at the 2024 European Society of Medical Oncology (ESMO) congress, which took place in Barcelona from Sept. 13 to Sept. 17.

The treatment is aimed at patients whose tumors had advanced after prior immune checkpoint inhibitor treatment, AVEO Oncology said Monday.

The clinical trial was designed to gauge the treatment of FOTIVDA, which is a vascular endothelial growth factor receptor tyrosine kinase inhibitor in combination with PD-1 inhibitor nivolumab, it said.

Price (KRW): â©321500.00, Change: â©+1000, Percent Change: +0.31%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2468513303?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-18 17:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2468513303","market":"sg","top_or_hot":-1,"title":"LG Chem's AVEO Oncology Presents RCC Drug Clinical Trial Results at 2024 ESMO","media":"MT Newswires Live","content":"<html><body><p> LG Chem's (KRX:051910) AVEO Oncology presented the Phase 3 clinical trial results of TiNivo-2 in patients with advanced metastatic renal cell carcinoma (RCC) at the 2024 European Society of Medical Oncology (ESMO) congress, which took place in Barcelona from Sept. 13 to Sept. 17.</p><p>The treatment is aimed at patients whose tumors had advanced after prior immune checkpoint inhibitor treatment, AVEO Oncology said Monday.</p><p>The clinical trial was designed to gauge the treatment of FOTIVDA, which is a vascular endothelial growth factor receptor tyrosine kinase inhibitor in combination with PD-1 inhibitor nivolumab, it said.</p><p>Price (KRW): â©321500.00, Change: â©+1000, Percent Change: +0.31%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LG Chem's AVEO Oncology Presents RCC Drug Clinical Trial Results at 2024 ESMO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLG Chem's AVEO Oncology Presents RCC Drug Clinical Trial Results at 2024 ESMO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-18 17:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>LG Chem's (KRX:051910) AVEO Oncology presented the Phase 3 clinical trial results of TiNivo-2 in patients with advanced metastatic renal cell carcinoma (RCC) at the 2024 European Society of Medical ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2468513303","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468513303","pubTimestamp":1726652171,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"LG Chem's  AVEO Oncology presented the Phase 3 clinical trial results of TiNivo-2 in patients with advanced metastatic renal cell carcinoma  at the 2024 European Society of Medical Oncology  congress, which took place in Barcelona from Sept. 13 to Sept. 17.The treatment is aimed at patients whose tumors had advanced after prior immune checkpoint inhibitor treatment, AVEO Oncology said Monday.The clinical trial was designed to gauge the treatment of FOTIVDA, which is a vascular endothelial growth factor receptor tyrosine kinase inhibitor in combination with PD-1 inhibitor nivolumab, it said.Price : 321500.00, Change: +1000, Percent Change: +0.31%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","RCC":"Ready Capital Corp","AVEO":"AVEO制药公司"},"translate_title":"LG化学旗下AVEO Oncology在2024年ESMO上展示RCC药物临床试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVEO":1,"RCC":1},"content_text":"LG Chem's (KRX:051910) AVEO Oncology presented the Phase 3 clinical trial results of TiNivo-2 in patients with advanced metastatic renal cell carcinoma (RCC) at the 2024 European Society of Medical Oncology (ESMO) congress, which took place in Barcelona from Sept. 13 to Sept. 17.The treatment is aimed at patients whose tumors had advanced after prior immune checkpoint inhibitor treatment, AVEO Oncology said Monday.The clinical trial was designed to gauge the treatment of FOTIVDA, which is a vascular endothelial growth factor receptor tyrosine kinase inhibitor in combination with PD-1 inhibitor nivolumab, it said.Price (KRW): â©321500.00, Change: â©+1000, Percent Change: +0.31%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2468513303"}